- Home
- VRNS vs RYTM Comparison
VRNS vs RYTM Comparison
Compare VRNS & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNS
- RYTM
- Stock Information
- Founded
- VRNS 2004
- RYTM 2008
- Country
- VRNS United States
- RYTM United States
- Employees
- VRNS N/A
- RYTM N/A
- Industry
- VRNS Computer Software: Prepackaged Software
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- VRNS Technology
- RYTM Health Care
- Exchange
- VRNS Nasdaq
- RYTM Nasdaq
- Market Cap
- VRNS 4.4B
- RYTM 4.3B
- IPO Year
- VRNS 2014
- RYTM 2017
- Fundamental
- Price
- VRNS $48.98
- RYTM $61.99
- Analyst Decision
- VRNS Buy
- RYTM Strong Buy
- Analyst Count
- VRNS 18
- RYTM 12
- Target Price
- VRNS $55.35
- RYTM $76.75
- AVG Volume (30 Days)
- VRNS 1.2M
- RYTM 525.0K
- Earning Date
- VRNS 07-28-2025
- RYTM 08-05-2025
- Dividend Yield
- VRNS N/A
- RYTM N/A
- EPS Growth
- VRNS N/A
- RYTM N/A
- EPS
- VRNS N/A
- RYTM N/A
- Revenue
- VRNS $573,351,000.00
- RYTM $136,863,000.00
- Revenue This Year
- VRNS $14.93
- RYTM $37.56
- Revenue Next Year
- VRNS $16.53
- RYTM $74.99
- P/E Ratio
- VRNS N/A
- RYTM N/A
- Revenue Growth
- VRNS 13.35
- RYTM 48.88
- 52 Week Low
- VRNS $36.53
- RYTM $39.46
- 52 Week High
- VRNS $60.58
- RYTM $69.89
- Technical
- Relative Strength Index (RSI)
- VRNS 58.10
- RYTM 47.67
- Support Level
- VRNS $48.77
- RYTM $60.70
- Resistance Level
- VRNS $50.64
- RYTM $62.65
- Average True Range (ATR)
- VRNS 1.09
- RYTM 2.39
- MACD
- VRNS -0.27
- RYTM -0.52
- Stochastic Oscillator
- VRNS 34.62
- RYTM 14.04
About VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.